Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286204 | 1.00 | HTR6 (0.43) | HTR6PPARGPPARAPPARDRXFP1 | |
| SCHEMBL6285407 | 0.91 | HTR6 (0.44) | HTR6PPARGPPARAPPARDDRD2 | |
| SCHEMBL6285411 | 0.91 | HTR6 (0.44) | HTR6PPARGPPARAPPARDDRD2 | |
| SCHEMBL6277929 | 0.91 | PLK1 (0.42) | HTR6PPARGPPARAPPARD | |
| SCHEMBL6277928 | 0.91 | PLK1 (0.42) | HTR6PPARGPPARAPPARD | |
| SCHEMBL6286257 | 0.89 | HTR6 (0.50) | HTR6PPARGPPARAPPARD | |
| SCHEMBL6286252 | 0.89 | HTR6 (0.50) | HTR6PPARGPPARAPPARD | |
| SCHEMBL6283899 | 0.88 | HTR6 (0.44) | HTR6PPARGDRD2HTR2A | |
| SCHEMBL6283907 | 0.88 | HTR6 (0.44) | HTR6PPARGDRD2HTR2A | |
| SCHEMBL6284975 | 0.86 | HTR6 (0.44) | HTR6PPARGPPARAPPARDDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906095-B2 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2A | HTR6 1/4885PPARG 1927/4885PPARA 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.